CN111542539B - 通过cd39/cd73轴恢复t细胞活性 - Google Patents

通过cd39/cd73轴恢复t细胞活性 Download PDF

Info

Publication number
CN111542539B
CN111542539B CN201880064186.3A CN201880064186A CN111542539B CN 111542539 B CN111542539 B CN 111542539B CN 201880064186 A CN201880064186 A CN 201880064186A CN 111542539 B CN111542539 B CN 111542539B
Authority
CN
China
Prior art keywords
antibody
amino acid
cancer
antibodies
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880064186.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN111542539A (zh
Inventor
S·尚特克斯
N·戈尔丁
C·帕图雷
I·普罗特
B·罗西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of CN111542539A publication Critical patent/CN111542539A/zh
Application granted granted Critical
Publication of CN111542539B publication Critical patent/CN111542539B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
CN201880064186.3A 2017-10-06 2018-10-05 通过cd39/cd73轴恢复t细胞活性 Active CN111542539B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762568812P 2017-10-06 2017-10-06
US62/568,812 2017-10-06
US201862686143P 2018-06-18 2018-06-18
US62/686,143 2018-06-18
PCT/EP2018/077217 WO2019068907A1 (en) 2017-10-06 2018-10-05 RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73

Publications (2)

Publication Number Publication Date
CN111542539A CN111542539A (zh) 2020-08-14
CN111542539B true CN111542539B (zh) 2023-10-20

Family

ID=63799006

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880064186.3A Active CN111542539B (zh) 2017-10-06 2018-10-05 通过cd39/cd73轴恢复t细胞活性

Country Status (11)

Country Link
US (2) US20190218308A1 (enExample)
EP (1) EP3692068B1 (enExample)
JP (1) JP7274469B2 (enExample)
KR (1) KR102710877B1 (enExample)
CN (1) CN111542539B (enExample)
AU (1) AU2018346447B2 (enExample)
BR (1) BR112020006809A2 (enExample)
CA (1) CA3074588A1 (enExample)
IL (1) IL273414A (enExample)
SG (1) SG11202002192QA (enExample)
WO (1) WO2019068907A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2238170T (pt) 2008-01-31 2017-02-21 Inserm - Inst Nat De La Santé Et De La Rech Médicale Anticorpos contra cd39 humano e seu uso para inibição da actividade de células t reguladoras
GB2545676A (en) * 2015-12-21 2017-06-28 Dublin Inst Of Tech Prediction of therapeutic response using vibrational spectroscopy
IL269150B2 (en) 2017-03-16 2025-04-01 Innate Pharma Cancer treatment preparations and methods
JP7113071B2 (ja) 2017-07-31 2022-08-04 トリシュラ セラピューティクス， インコーポレイテッド 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法
MX2020011588A (es) 2018-05-03 2020-12-07 Shanghai Epimab Biotherapeutics Co Ltd Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
TWI870353B (zh) 2018-06-18 2025-01-21 法商天賜製藥公司 用於治療癌症之組合物及方法
CN113454121B (zh) * 2019-08-21 2022-03-08 和铂医药(上海)有限责任公司 抗cd73抗体及其应用
KR20220050971A (ko) * 2019-08-27 2022-04-25 엘피사이언스 (쑤저우) 바이오파마, 엘티디. 신규 항-cd39 항체
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
TW202118791A (zh) 2019-11-05 2021-05-16 大陸商北京加科思新藥研發有限公司 對cd39具有特異性的結合分子及其用途
CA3165384A1 (en) * 2019-12-19 2021-06-24 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
CN114106160A (zh) * 2020-08-28 2022-03-01 安源医药科技（上海）有限公司 抗SARS-CoV-2病毒单克隆抗体及应用
US20220133902A1 (en) * 2020-11-04 2022-05-05 Heidelberg Pharma Research Gmbh Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy
JP2024507823A (ja) * 2021-02-19 2024-02-21 ヤンセン バイオテツク，インコーポレーテツド 免疫監視を増強するために制御性ｔ細胞を標的化するための材料及び方法
AU2022236461A1 (en) 2021-03-19 2023-10-05 Heidelberg Pharma Research Gmbh B-lymphocyte specific amatoxin antibody conjugates
CN119569881B (zh) 2022-03-03 2025-11-07 艾库斯生物科学有限公司 抗cd39抗体及其用途
US20250361314A1 (en) * 2022-06-08 2025-11-27 Shanghai Huaota Biopharmaceutical Co., Ltd. Cd39/cd73 bispecific antigen binding protein and use thereof
WO2024197020A2 (en) * 2023-03-21 2024-09-26 Beam Therapeutics Inc. Immunosuppressant-resistant modified allogeneic modified immune cells and methods for use thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387645B1 (en) * 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
WO2009095478A1 (en) * 2008-01-31 2009-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
CN104244977A (zh) * 2012-02-07 2014-12-24 先天制药公司 Mica结合剂
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
CN106852149A (zh) * 2014-10-10 2017-06-13 依奈特制药公司 Cd73阻断
CN110382544A (zh) * 2017-03-16 2019-10-25 先天制药公司 用于治疗癌症的组合物和方法
CN111372606A (zh) * 2017-11-15 2020-07-03 先天制药公司 增强atp释放作用
CN113784981A (zh) * 2019-04-23 2021-12-10 先天制药公司 Cd73阻断抗体
CN114127121A (zh) * 2019-08-12 2022-03-01 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
CN104548091A (zh) 2008-02-11 2015-04-29 治疗科技公司 用于肿瘤治疗的单克隆抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
BR122022000334B1 (pt) 2011-08-01 2023-03-21 Genentech, Inc Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek
FR3011240A1 (fr) 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
PL3081576T3 (pl) 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
WO2015164573A1 (en) 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer
CN112778418B (zh) 2014-11-10 2025-04-22 免疫医疗有限公司 对cd73具有特异性的结合分子及其用途
HK1246304A1 (zh) * 2014-11-11 2018-09-07 Medimmune Limited 包含抗cd73抗体和a2a受体抑制剂的治疗组合及其用途
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
EP3259288A1 (en) 2015-02-20 2017-12-27 Innate Pharma Cd73 blockade
US20190153113A1 (en) 2015-11-23 2019-05-23 Innate Pharma Cd39 vascular isoform targeting agents
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017100670A1 (en) 2015-12-09 2017-06-15 Corvus Pharmaceuticals, Inc. Humanized anti-cd73 antibodies
EA038565B1 (ru) 2016-01-08 2021-09-15 Аркус Байосайенсиз, Инк. Модуляторы экто-5'-нуклеотидазы и их применение
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
TWI786072B (zh) 2016-11-18 2022-12-11 美商阿克思生物科學有限公司 Cd-73介導免疫抑制之抑制劑

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387645B1 (en) * 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
WO2009095478A1 (en) * 2008-01-31 2009-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
CN104244977A (zh) * 2012-02-07 2014-12-24 先天制药公司 Mica结合剂
CN106852149A (zh) * 2014-10-10 2017-06-13 依奈特制药公司 Cd73阻断
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
CN110382544A (zh) * 2017-03-16 2019-10-25 先天制药公司 用于治疗癌症的组合物和方法
CN111372606A (zh) * 2017-11-15 2020-07-03 先天制药公司 增强atp释放作用
CN113784981A (zh) * 2019-04-23 2021-12-10 先天制药公司 Cd73阻断抗体
CN114127121A (zh) * 2019-08-12 2022-03-01 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion;Sebastian Fm Häusler;《American Journal of translational research》;第6卷(第2期);第129-139页 *
CD39和CD73在CD4+CD25highFoxp3+调节性T细胞发挥免疫抑制功能中的作用研究;韩凌等;《现代免疫学》(第2期);第101-106页 *
Targeting the CD73-adenosine axis in immuno-oncology;DavidAllard;《Immunology Letters》;第5卷;第31-39页 *

Also Published As

Publication number Publication date
BR112020006809A2 (pt) 2020-10-06
JP7274469B2 (ja) 2023-05-16
CA3074588A1 (en) 2019-04-11
KR20200060471A (ko) 2020-05-29
AU2018346447A1 (en) 2020-03-19
KR102710877B1 (ko) 2024-09-26
EP3692068A1 (en) 2020-08-12
CN111542539A (zh) 2020-08-14
SG11202002192QA (en) 2020-04-29
IL273414A (en) 2020-05-31
AU2018346447B2 (en) 2025-06-19
US20230099801A1 (en) 2023-03-30
JP2020536109A (ja) 2020-12-10
WO2019068907A1 (en) 2019-04-11
US20190218308A1 (en) 2019-07-18
EP3692068B1 (en) 2022-12-07

Similar Documents

Publication Publication Date Title
CN111542539B (zh) 通过cd39/cd73轴恢复t细胞活性
JP7132981B2 (ja) Ｃｄ７３遮断
CN110382544B (zh) 用于治疗癌症的组合物和方法
US11130817B2 (en) CD73 blocking agents
JP7530913B2 (ja) Ｃｄ７３遮断抗体
AU2018368541B2 (en) Potentiating the effect of ATP release
JP7500442B2 (ja) 癌を処置するための組成物及び方法
US20180030144A1 (en) Cd73 blockade
EA044293B1 (ru) Восстановление активности t-клеток посредством системы cd39/cd73
HK40040395B (zh) 用於治疗癌症的组合物和方法
BR112017006464B1 (pt) Anticorpo isolado, composição farmacêutica, uso de um anticorpo e anticorpo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant